MeiraGTx Gets $30 Million Investment From Sanofi
By Will Feuer
MeiraGTx Holdings said it has received a $30 million investment from French pharmaceutical company Sanofi, and said the company has been approached by multiple parties about certain assets.
MeiraGTx, a clinical-stage gene-therapy company, said Sanofi bought 4 million shares at a price of $7.50 a share. Sanofi will receive a right of first negotiation for the use of MeiraGTx's Riboswitch gene-regulation technology for various uses, including in GLP-1 drugs.
The company said it is also actively pursuing options after multiple parties approached MeiraGTx with interest in some of the company's assets. MeiraGTx has hired Evercore as a financial advisor and Wachtell, Lipton, Rosen & Katz as legal advisor.
Write to Will Feuer at Will.Feuer@wsj.com
(END) Dow Jones Newswires
October 30, 2023 07:59 ET (11:59 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Powell Unfazed By Sticky Inflation, but Rate Cuts Are Far Off
-
After Earnings, Is Microsoft Stock a Buy, a Sell, or Fairly Valued?
-
Best- and Worst-Performing Stocks of April 2024
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Small-Cap and Value Stocks Are Undervalued
-
Why We Expect the Job Market’s Slowdown to Renew in 2024
-
5 Undervalued Stocks to Buy to Play a Little Defense
-
10 Top-Performing Dividend Stocks of the Month
-
Marathon Petroleum Earnings: No Change to Competitive Position, but Shares Look Expensive
-
Charlie Munger and How Not to Invest
-
Look Inside Berkshire Hathaway’s Portfolio Before Its Annual Meeting
-
After Earnings, Is AT&T Stock a Buy, a Sell, or Fairly Valued?
-
Mastercard Earnings: A Stable Environment Highlights the Firm’s Strengths
-
Pfizer Earnings: Solid Results Supported by Steady Tracking Toward $4 Billion In Cost Cuts
-
Starbucks Earnings: Not a Lot to Like About Results as Global Traffic Sputters